

Date: 7 December 2017 Sydney, Australia

**ASX: NOX** 

**Noxopharm Limited** 

ABN 50 608 966 123

### **Registered Office:**

Suite 1 Level 6 50 Queen St Melbourne VIC 3000 Australia

#### **Operational Office:**

Suite 3, Level 4 828 Pacific Highway Gordon NSW 2072 Australia

# Board of Directors Mr Peter Marks

Chairman Non-Executive Director

#### **Dr Graham Kelly**

Chief Executive Officer Managing Director

## **Dr Ian Dixon**

Non-Executive Director

ASX Limited 20 Bridge Street SYDNEY NSW 2000

## NOTICE UNDER SECTION 708A(5)(E) OF THE CORPORATIONS ACT 2001 (CTH)

For the purposes of section 708A(5)(e) of the Corporations Act 2001 (Cth), Noxopharm Limited (ASX: NOX) (**Noxopharm** or the **Company**) hereby provides notice that today it has issued 807,500 new fully paid ordinary shares, from the exercise of unlisted options, at an exercise price of \$0.30 per share, with an expiry date of 28 February 2021 (**New Shares**). The unlisted options are from all of the 357,500 Restricted Options previously issued under its Prospectus and released from escrow on 8 January 2017 and part of the 3,277,857 Restricted Options previously issued under its Prospectus and released from escrow on 1 April 2017. The New Shares will rank equally in respects with existing ordinary shares.

Please see attached Appendix 3B for more details.

NOX gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

- 1 The New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
- 2 As at the date of this notice, NOX has complied with:
  - (a) The provisions of Chapter 2M of the Corporations Act as they apply to NOX; and
  - (b) Section 674 of the Corporations Act.
- 3 As at the date of this notice, there is no information that is "excluded information" of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.

For and on behalf of the Board,

Yours faithfully,

David Franks

**Company Secretary**